Transcatheter aortic valve replacement using the iSleeve expandable sheath in small femoral arteries

Natalie Glaser, Crochan J. O’Sullivan, Nawzad Saleh, Dinos Verouhis, Magnus Settergren, Rickard Linder, Andreas Rück

ABSTRACT

Background Small femoral arteries have been associated with a higher risk of vascular complications in transfemoral transcatheter aortic valve replacement (TAVR). We investigated the feasibility and safety of TAVR in patients with small femoral arteries.

Methods In this observational study, we included 82 patients who underwent transfemoral TAVR with the ACURATE neo system using the expandable 14F iSleeve sheath between 2018 and 2019 at Karolinska University Hospital, Sweden. Of these, 41 patients had a minimal femoral artery diameter of ≥5.5 mm (mean 6.5, range 5.5–9.2), and 41 patients had a minimal femoral artery diameter <5.5 mm (mean 4.9, range 3.9–5.4).

Results There was no significant difference in major vascular and bleeding complications between the small femoral artery group (7%) and the normal femoral artery group (2%) (p=0.62). The total of major and minor vascular complications did not differ significantly according to femoral artery size (17% vs 5%) (p=0.16). The iSleeve sheath was not correlated with any of the complications. The use of the iSleeve sheath was unsuccessful in four patients (5%), of which one patient had a small femoral artery diameter.

Conclusion Transcatheter TAVR with the ACURATE neo system using the iSleeve sheath is a promising method for patients with small femoral arteries even though we found a trend towards higher rates of complications in these patients. The use of expandable sheaths may expand the spectrum of patients that can be treated with transfemoral TAVR and thus may improve the prognosis in patients with severe aortic valve stenosis.

INTRODUCTION

The use of transcatheter aortic valve replacement (TAVR) for treatment in patients with severe aortic valve stenosis has seen a rapid increase during the last decade. In TAVR, transfemoral access is associated with better outcomes compared with alternative routes of access. One of the main limitations with transfemoral TAVR is the risk of major vascular complications, which occur in 4.5%–8.0% of the patients. Vascular complications have been associated with increased risk of bleeding, need for blood transfusion and mortality. Newer-generation transfemoral TAVR system sheaths are indicated for use in patients with femoral artery diameters of at least 5.5 mm, and approximately 10% of patients cannot undergo transfemoral TAVR. Small femoral artery diameters have been associated with a higher risk of vascular complications and mortality. Therefore, we performed a study using the expandable 14F iSleeve sheath (Boston Scientific, Marlborough, Massachusetts, USA) to analyse feasibility and safety of transfemoral TAVR in patients with femoral artery diameters below 5.5 mm.
The small femoral artery group (minimal luminal diameter ≥ 5.5 mm and 41 consecutive patients with a femoral artery diameter of <5.5 mm). The sheath-access ratio (SFAR) was calculated by dividing the sheath’s outer diameter at the expandable section (7.3 mm) by the femoral artery minimal luminal diameter.

The iSleeve sheath has a 14F profile (4.8 mm) when not expanded and a 32 cm working length. It is compatible with the ACURATE neo system and CE marked since early 2018. Specifically, the iSleeve diameter is 7.3 mm at the expandable section when the valve is crossing the sheath, and 7.9 mm at the arteriotomy site. Four experienced invasive cardiologists who never used the iSleeve sheath before the start of this study performed all 82 TAVR procedures. Baseline and operative characteristics were gathered at the time of intervention, and data were collected retrospectively from medical records with information about outcomes. After all data were collected; data were anonymised; and data management and statistical analysis proceeded with fully anonymised data.

Outcomes
The primary objective was feasibility and safety of TAVR with the ACURATE neo system in patients with small femoral artery diameters using the iSleeve expandable sheath. Feasibility was defined as the ability to successfully introduce the iSleeve sheath and to cross and retrieve through the sheath with predilation and postdilation balloons, without the need to change to another sheath. Safety was defined as in-hospital major or minor vascular complications, or major bleeding complications. These outcomes were evaluated according to the updated Valve Academic Research Consortium-2 criteria.5

Procedural technique and details
The TAVR procedure performed at Karolinska University Hospital followed routine medical procedures and was performed with local anaesthesia in all patients, with fentanyl as analgesia when needed. Ultrasound-guided micropuncture was used for femoral access. The iSleeve sheath was introduced under fluoroscopic guiding. The introduction of the sheath was preceded by balloon dilation of the iliac artery in seven patients. Predilation of the aortic stenosis was performed with a True balloon (Bard Peripheral Vascular, Tempe, Arizona, USA) at a size 1–2 mm smaller than the perimeter derived mean annular diameter. The transcatheter aortic valve prosthesis was implanted with standard techniques (moving image 1, online supplemental data). Intravenous unfractionated heparin was administered during the procedure with a target activated clotting time of 250s. Protamine was used to reverse the heparin effect if deemed beneficial by the operator. The 18F MANTA device (Teleflex, Wayne, Pennsylvania, USA) was used for vascular closure. Post procedural peripheral blood flow was checked with manual palpation and pulsed-wave ultrasound in the superficial femoral artery after each procedure. Light compression with a manual femoral compression device, Femostop (Abbott Vascular, Abbott Park, Illinois, USA), was used routinely for 3 hours postoperatively. The
Interventional cardiologist was responsible for selecting the optimal preoperative and postoperative antithrombotic regimen.

Statistical analysis
Baseline characteristics were described as means and SD for continuous variables and as numbers and proportions for categorical variables. Fisher’s exact test was used to statistically assess the rate of complications between small and normal femoral artery diameters. Stata V.16.1 was used for data management and statistical analysis.

RESULTS
Baseline and operative characteristics
Among the 82 patients who were included in the study, the average femoral artery diameter was 5.7 mm in the total study cohort, 6.5 mm in the normal vessel group and 4.9 mm in the small vessel group (moving image 2, online supplemental data). Figure 1 illustrates the distribution of femoral artery diameters. The mean age was 81.7 (SD 6.6) years; 55% were women; and 35% had undergone previous percutaneous coronary intervention or coronary artery bypass grafting. The mean EuroSCORE II was 7.3 (SD 10.9), and the mean SFAR was 1.33 (SD 0.2). Patients in the small femoral artery group were younger and had a lower body mass index, a higher frequency of peripheral artery disease and a lower EuroSCORE II. Protamin was given to reverse the effect of the unfractionated heparin in 11 (27%) and 12 (29%) patients in the normal femoral artery group and the small femoral artery group, respectively. Balloon dilatation of the iliac artery was necessary to get the TAVR system through the sheath in eight patients in the small femoral artery group and in no patients in the normal femoral artery.
Table 2: Operative characteristics in 82 patients who underwent transcatheter aortic valve replacement with the ACURATE neo system and the iSleeve sheath at Karolinska University Hospital, Stockholm, Sweden, between March 2018 and February 2019.

<table>
<thead>
<tr>
<th></th>
<th>All patients N=82</th>
<th>Normal vessel diameter* N=41</th>
<th>Small vessel diameter* N=41</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin dose (IU), mean (SD)</td>
<td>5235 (1527)</td>
<td>5113 (1347)</td>
<td>5353 (1693)</td>
</tr>
<tr>
<td>Highest activated clotting time (seconds), mean (SD)</td>
<td>283 (49)</td>
<td>283 (51)</td>
<td>284 (44)</td>
</tr>
<tr>
<td>Protamin given</td>
<td>23 (28)</td>
<td>11 (27)</td>
<td>12 (29)</td>
</tr>
<tr>
<td>Second arterial access through radial artery</td>
<td>59 (72)</td>
<td>36 (88)</td>
<td>23 (56)</td>
</tr>
<tr>
<td>Valve size (mm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>12 (15)</td>
<td>6 (15)</td>
<td>6 (15)</td>
</tr>
<tr>
<td>25</td>
<td>36 (44)</td>
<td>17 (43)</td>
<td>19 (46)</td>
</tr>
<tr>
<td>27</td>
<td>33 (41)</td>
<td>17 (43)</td>
<td>16 (39)</td>
</tr>
</tbody>
</table>

Data are n (%) unless otherwise noted.
*Normal vessel diameter defined as at least 5.5 mm and small vessel diameter below 5.5 mm.

Feasibility and safety
There were no in-hospital deaths and the in-hospital data were complete for all patients. There was no significant difference in major vascular and bleeding complications between the small femoral artery group (7%) and the normal femoral artery group (2%) (p=0.62). Also, the total of major and minor vascular complications did not differ significantly according to femoral artery size (17% vs 5%) (p=0.16). The same four patients who had a major vascular complication also had major bleeding complications and, additionally, two had minor vascular complications. Minor vascular complications occurred in five additional patients. Consequently, any type of vascular or bleeding complication occurred in nine patients (11%). In these patients, an ACURATE neo valve size medium was implanted in seven patients, small in one patient and large in one patient. None of the complications that occurred were caused by the iSleeve sheath. For distribution of femoral artery diameters and the occurrence of major complications, see figure 1. There was no significant association between a sheath-to-femoral-artery ratio of >1.05 and higher complication rates (p=0.60).

Details on complications can be found in table 3. Of the patients with major complications, one patient had a dissection and thrombus distal to the puncture site that required aspiration and surgery. The same patient also had bleeding from the puncture site requiring blood transfusion. Two patients developed a pseudoaneurysm at the access site that was treated with thrombin injection. These patients also had major bleeding. One patient suffered occlusion of the femoral artery requiring surgical and blood transfusion. Of the patients with minor complications, three patients suffered access site bleedings that were treated with endovascular stenting or balloon therapy. One patient suffered femoral occlusion that required unplanned endovascular balloon therapy. The seventh patient with minor vascular complication had a stenosis at the access site, which was treated with endovascular balloon at the end of the procedure. The use of the iSleeve sheath was unsuccessful in four patients (5%), of which three had a femoral artery diameter of at least 5.5 mm. One of these patients had a stent in the iliac artery (and a totally occluded iliac artery at the other side), which could not be passed with any sheath or valve prosthesis, despite balloon dilatation of the stent. In a second patient, the iSleeve sheath was damaged when the delivery system was retrieved and subsequently replaced with a 20F sheath. In the third patient, the iSleeve sheath kinked and was replaced with a 20F sheath; and in the fourth patient, the iSleeve sheath invaginated after valve delivery and was replaced with an 18F sheath.

DISCUSSION
In this observational cohort study, we found that patients with small femoral arteries who underwent transfemoral TAVR with the ACURATE neo system using the expandable iSleeve sheath had an acceptable rate of major vascular and bleeding complications (7%). The mean femoral artery diameter in the small femoral artery group was 4.9 mm (range 3.9–5.4 mm), which is smaller than in previous studies.7 8 12 The small femoral artery group included eight patients where balloon dilatation of the iliac artery was necessary to get the TAVR system through the sheath. There was a trend towards more complications in patients with small compared with normal femoral artery diameters, but this association was not statistically significant and may be explained by the small sample size. Transfemoral TAVR using the expandable iSleeve sheath was feasible and safe in patients with both small and normal femoral artery diameters. Although we could find no significant difference in vascular complications between normal and small size femoral arteries, there was a numerical trend towards more complications in patients with small femoral...
Table 3  Detailed description of patients with complications according to the VARC criteria, and unsuccessful use of the iSleeve sheath

<table>
<thead>
<tr>
<th>Patient</th>
<th>iSleeve unsuccessful</th>
<th>VARC major vascular complication</th>
<th>VARC major bleeding complication</th>
<th>VARC minor vascular complication</th>
<th>Age</th>
<th>Sex</th>
<th>Access vessel diameter</th>
<th>Calcification (0–3)</th>
<th>Tortuosity (0–3)</th>
<th>SFAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>Dissection and thrombus distal to puncture site, required aspiration and vascular surgery</td>
<td>Bleeding from access site requiring transfusion of two units of blood</td>
<td>Pseudoaneurysm at access site</td>
<td>87</td>
<td>Female</td>
<td>5.8</td>
<td>2</td>
<td>2</td>
<td>1.26</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>Pseudoaneurysm at access site leading to major bleeding</td>
<td>Bleeding at access site requiring transfusion of three units of blood</td>
<td>Pseudoaneurysm at access site</td>
<td>89</td>
<td>Female</td>
<td>5.4</td>
<td>3</td>
<td>1</td>
<td>1.35</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>Pseudoaneurysm at access site leading to major bleeding</td>
<td>Bleeding at access site requiring transfusion of three units of blood</td>
<td>Pseudoaneurysm at access site</td>
<td>85</td>
<td>Male</td>
<td>5.3</td>
<td>2</td>
<td>1</td>
<td>1.38</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>Occlusion of femoral artery after MANTA, required vascular surgery</td>
<td>Bleeding after vascular surgery requiring transfusion of two units of blood</td>
<td>—</td>
<td>80</td>
<td>Female</td>
<td>3.9</td>
<td>3</td>
<td>2</td>
<td>1.87</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td>—</td>
<td>—</td>
<td>Bleeding at access site with unplanned endovascular stenting</td>
<td>76</td>
<td>Female</td>
<td>4.1</td>
<td>2</td>
<td>1</td>
<td>1.78</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>—</td>
<td>—</td>
<td>Stenosis at access site with unplanned endovascular balloon therapy</td>
<td>74</td>
<td>Female</td>
<td>6</td>
<td>1</td>
<td>1</td>
<td>1.22</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>—</td>
<td>—</td>
<td>Bleeding at access site with unplanned endovascular stenting</td>
<td>88</td>
<td>Female</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>1.46</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>—</td>
<td>—</td>
<td>Bleeding at access site with unplanned endovascular balloon therapy</td>
<td>95</td>
<td>Female</td>
<td>4.9</td>
<td>2</td>
<td>1</td>
<td>1.49</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>—</td>
<td>—</td>
<td>Femoral occlusion with unplanned endovascular balloon therapy</td>
<td>71</td>
<td>Male</td>
<td>4.4</td>
<td>2</td>
<td>2</td>
<td>1.66</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>Could not pass stent in iliac artery with any sheath or valve prosthesis</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>88</td>
<td>Male</td>
<td>5.6</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>Damaged sheath</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>85</td>
<td>Female</td>
<td>5.5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>Sheath kinked</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>81</td>
<td>Male</td>
<td>8</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>Invagination of iSleeve after valve delivery</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>85</td>
<td>Female</td>
<td>4.7</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

SFAR, sheath-to-femoral artery ratio; VARC, Valve Academic Research Consortium.
arteries, and it seems plausible that such an association exists. Some previous studies have shown an association between small access artery size and vascular complications. A smaller study by Abu Saleh et al, using a balloon-expandable and recollapsible 19F sheath, included 13 patients with a minimal luminal diameter of <5.0 mm and 51 patients with larger arteries, and found no major vascular complications at all. In the study by Abu Saleh et al, a balloon-expandable and recollapsible 19F sheath was used. Compared with this study, the patients in our study had smaller artery diameters, and the study sample was larger.

Expandable sheaths, like the 14F iSleeve, have one or more longitudinal slits with thinner material where the sheath is able to expand. However, this decreases the longitudinal strength of the sheath, which might explain why the iSleeve sheath was kinked either during insertion or after retrieval of the predilatation balloon in three patients in our study cohort. Of note, the iSleeve has undergone a slight redesign subsequently.

Previous studies showed that an SFAR of >1.05 was associated with an increased risk of vascular complications. However, other studies could not confirm this association. In our study, no association between higher SFAR and rate of vascular complications could be found. Our results strengthen the results previously reported that SFAR is not a predictor of vascular complications. Furthermore, most complications occurred in patients who received an ACURATE neo valve size medium. However, these results have to be interpreted with caution due to the small number of events in our study.

As TAVR with non-femoral access has been associated with adverse outcomes, it would be valuable to find ways to enable transfemoral access also in patients who have previously been considered ineligible for transfemoral access. For example, the use of intravascular lithotripsy could be one way to facilitate transfemoral access. In the present study, we used an expandable sheath to facilitate transfemoral access. In our opinion, a 7% rate of major vascular complications but no mortality in patients with small sized femoral arteries is acceptable, considering the alternative with non-femoral access and the associated risks.

Strengths and limitations
The number of patients included and the events recorded in our study were limited, and therefore, it is possible that a significant difference in the rate of complications between patients with normal and small access vessels could not be detected. Furthermore, we did not include a control group that underwent TAVR with a traditional sheath during the same time period. Thus, the results of this study should be regarded as merely hypothesis-generating in terms of the feasibility of transfemoral TAVR with the iSleeve sheath. Also, the incidence of vascular complications is largely affected by the puncture and closure technique used. We used an ultrasound-guided micropuncture technique and the MANTA device for vascular closure in all patients. Thus, our results may not be generalisable to settings with other puncture and closure techniques. A strength of this study is that we included 82 consecutive patients who underwent transfemoral TAVR, which increases the generalisability and the internal validity. Other strengths include the complete follow-up for all outcomes and the use of MDCT in all patients for evaluation of the minimum femoral artery diameter.

CONCLUSION
Transfemoral TAVR with the ACURATE neo system using the expandable iSleeve sheath is a promising method for patients with small femoral arteries. However, there was a numerical trend towards higher rates of complications in these patients, and our results should be confirmed in larger study populations. The use of expandable sheaths may expand the spectrum of patients that can be treated with transfemoral TAVR and thus improve the prognosis in patients with severe aortic valve stenosis.

Contributors NG, CJO, NS, DV, MS, RL and AR conceived and designed the research. CJO, NS, CV, MS, RL and AR acquired the data. NG and AR performed statistical analyses. NG, CJO, NS, DV, MS, RL and AR contributed to the interpretation of data. NG and AR drafted the manuscript. NG, CJO, NS, DV, MS, RL, and AR made critical revision of the manuscript for key intellectual content and have seen and approved the final version.

Funding This work was supported by Boston Scientific, the Swedish Heart-Lung Foundation (grant number 20190570 to NG), the Swedish Society of Medicine (grant number SLS-934749 to NG), Region Stockholm (clinical postdoctoral appointment to NG), a regional ALF agreement between Stockholm County Council and the Karolinska Institutet (to NG), Capio Research Foundation (grant number 2019-3239 to NG), Eva and Oescar Ahrén Research Foundation (to NG), and the Seraphim Hospital Foundation (to NG).

Disclaimer Boston Scientific funded the study and had a role in study design, but not in data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests Boston Scientific funded the study and had a role in study design, but not in data collection and analysis, decision to publish, or preparation of the manuscript. The authors had full responsibility for data collection, data analysis, writing for the manuscript, and for the decision to submit for publication. Some of the authors serve as a proctor/advisory board member for Boston Scientific (NS, MS, RL and AR), Abbott Vascular (MS), WL Gore (MS), Edwards Lifesciences (AR) and Medtronic (MS and A.R).

Patient consent for publication Not required.

Ethics approval This observational cohort study was approved by the regional Human Research Ethics Committee, Stockholm, Sweden, and the need for informed consent was waived. The study adheres to the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits
REFERENCES